首页> 外文期刊>Seminars in cancer biology >MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention
【24h】

MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention

机译:MicroRNA调节K-RAS在胰腺癌中的k-ras和治疗干预机会

获取原文
获取原文并翻译 | 示例
           

摘要

The Ras family of GTPases is involved in cell proliferation, cell survival, and angiogenesis. It is upregulated in several cancers, including pancreatic cancer (PC) and leads to uncontrolled growth and aggressiveness. PC is well known to be a lethal disease with poor prognosis, plagued by limited therapeutic modalities. MicroRNAs (miRNAs), which are short non-coding RNA molecules, have recently emerged as regulators of signaling networks and have shown potential to target pathway components for therapeutic use in several malignancies. K-Ras mutations are widespread in PC cases (90%), with mutations detectable as early as pancreatic intraepithelial neoplasias and in later metastatic stages alike; therefore, these mutations in K-Ras are obvious drivers and potential targets for PC therapy. Several K-Ras targeting miRNAs have lately been discovered, and many of them have shown promise in combating pancreatic tumor growth in vitro and in mouse models. However, the field of miRNA therapy is still in its infancy, and miRNA mimics or anti-miRNA oligonucleotides that target Ras pathway have thus far not been evaluated in PC patients. In this review, we summarize the role of several miRNAs that regulate oncogenic K-Ras signaling in PC, with their prospective roles as therapeutic agents for targeting K-Ras pathway.
机译:RAS系列GTP酶参与细胞增殖,细胞存活和血管生成。它在几种癌症中上调,包括胰腺癌(PC)并导致不受控制的生长和侵袭性。众所周知,PC是一种致命疾病,预后差,治疗方式有限困扰。较短的非编码RNA分子的microRNAs(miRNA)最近被出现为信号通信网络的调节器,并且已经显示出靶向途径组分的可能性在几种恶性肿瘤中的治疗用途。 K-RAS突变在PC壳体(90%)中是普遍的,突变早期可检测为胰腺上皮内瘤,并且在后续转移阶段相同;因此,K-RA中的这些突变是PC疗法的明显驱动因素和潜在目标。最近发现了几种靶向miRNA的K-RAS,其中许多人已经显示出在体外和小鼠模型中对抗胰腺肿瘤生长的希望。然而,MiRNA治疗领域仍处于其初期,并且靶RAS途径的miRNA模拟物或抗mIRNA寡核苷酸尚未在PC患者中进行评估。在本综述中,我们总结了几种miRNA的作用,该方法调节PC中的致癌K-RAS信号传导,其前瞻性作用作为靶向K-RAS途径的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号